The Record Special Sections Health Quarterly 10-27-2019 | Página 2

2 ❚ SUNDAY, OCTOBER 27, 2019 ❚ THE RECORD HEALTH QUARTERLY / ADVERTISING SECTION Prostate Cancer: Accurate Diagnosis of the Disease CONTINUED FROM PAGE 1 and men with family histories of the disease are advised to get screenings by age 45. The PSA test is a blood test used to screen for prostate can- cer. PSA is a protein produced by both cancerous and noncancer- ous tissue in the prostate, a small gland that sits below the bladder in men. There is controversary and ongoing conversations surround- ing the limitations and reliability of the PSA test, therefore, it’s important to note that the test should be administered — based on age and family history — on an individualized basis. This diagnostic approach to screening has received advance- ments in the last few years but is not an exact science. Although a PSA screening above four will raise suspicions, there may be underlying causes for the elevated reading. A prostate infection, sexual intercourse, even a long bike ride can change PSA levels. Certain medications can lower PSA indicating no cancer when that might not be the case. “A significant change in a read- ing may be more concerning than a number that is consistently high,” says Dr. James Orsini, Jr., an oncologist and hematologist at New Jersey Cancer Care & Blood Disorders. “So, for example, a high reading of 5 that changes to a 5.5 may be less of a red flag than a low reading of 2 that elevates to 4.” Many doctors also recommend a rectal exam as a relatively simple test in the screening of prostate cancer. At the forefront in prostate screening is a urinary test that could eventually surpass the PSA. Once a patient is given an alert, a physician will order a 12-core prostate biopsy removing small samples of tissue from 12 differ- ent regions of the area to detect for prostate cancer. Fusion-guided biopsies are new technologies available today that help with predicting prostate cancer aggres- siveness and in detection. Two notable area hospitals — The Valley Hospital and Hackensack University Medical Center — have made this technology available to their patients. “These mul- tiparametric MRIs have com- pletely changed the paradigm in diagnosing prostate cancer,” notes Dr. Michael Stifelman, chair, Department of Urology and director, Robotic Surgery at Hackensack University Medical Center. “This procedure also helps patients in selecting the best modality of treatment.” Valley-Mount Sinai Comprehensive Cancer Care offers the UroNav Fusion Biopsy System helping to diagnose pros- tate cancer with pinpoint accura- cy. This targeted MRI/ultrasound fuses pre-biopsy MRI images with ultrasound-guided biopsy images in real time to target suspicious areas for biopsy. “Fusion Biopsy greatly improves on the standard Dr. James Orsini, Jr. technique by more accurately diagnosing the disease. Prostate cancer can be hard to detect as patients often show no symptoms at the time of diagnosis,” says Dr. Thomas Kole, PhD, Radiation oncologist, Valley-Mount Sinai Comprehensive Cancer Care. Revolutionary means of detec- tion and screening are changing the course of prostate cancer offering a more individualized approach for treatment. A newly developed series of genetic tests helps in identifying gene sig- natures that might reveal men who are at a higher risk of pros- tate cancer. The 4Kscore Test is a blood test that accurately identifies the risk of aggressive prostate cancer, playing a critical role in helping to avoid unneces- sary prostate biopsies resulting from inconclusive PSA tests. For patients with advanced disease, combination therapies are show- ing signs of improvement. TREATMENT Not all prostate cancer cases need to undergo treatment right away. Depending on age, the can- cer may not cause trouble within a person’s lifetime. For those patients, doctors will keep an active surveillance with PSA test- ing and periodic new biopsies. See PROSTATE Page 18 Urogynecology at New Jersey Urology We’re pleased to announce that Dr. Nyarai Mushonga will provide urogynecological services FQ KH1(( "(* 8(10() /16'6L) '6EI%6Q0J O1J #-0H6QLI F0 G6I1, E(1%9(, G) KH( $R(1FEIQ !6I1, 6C SG0K(K1FE0 IQ, @)Q(E6'6L) IQ, G6I1, ('FLFG'( FQ C(RI'( 4('+FE R(,FEFQ( IQ, 1(E6Q0K1-E%+( surgery specializing in: ? ? • • ? ? • ? !'I,,(1 ,)0C-QE%6Q ,F061,(10 !'I,,(1 4IFQ Cystocele Rectocele A(EI' FQE6Q%Q(QE( A(RI'( 4('+FE 4IFQ Fistulas &IGFI' H)4(1K164H) ? ? ? ? ? ? • S+(1IE%+( G'I,,(1 #6-QK 7'(I0IQK $+(Q-(N 3-FK( D>P M(0K S1IQL(N "8 P=P>D